U.S. Markets open in 34 mins.

Kindred Biosciences, Inc. (KIN)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
8.25+0.35 (+4.43%)
At close: 4:00PM EDT
People also watch
PETXDRNAKPTIVCYTKMDA

Kindred Biosciences, Inc.

1555 Bayshore Highway
Suite 200
Burlingame, CA 94010
United States
650-701-7901
http://www.kindredbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedAge
Dr. Richard Chin M.D.Co-Founder, Chief Exec. Officer, Pres, Interim Chief Financial Officer and Director619kN/A50
Ms. Denise M. BeversCo-Founder, Chief Operating Officer and Sec.487.5kN/A50
Dr. Stephen Sundlof D.V.M., PH.D.Chief Scientific Officer and Exec. VP of Regulatory Affairs & Quality375.1kN/A66
Dr. Jennifer ElliottVP of Legal Affairs and Intellectual PropertyN/AN/AN/A
Dr. Noe Reyes D.V.MMedical DirectorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic syndrome. It is also developing biologics programs, such as KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) treatment for newborn foals; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a novel biologics with certain advantages over antibodies, including bispecific binding. The company was founded in 2012 and is headquartered in Burlingame, California.

Corporate Governance

Kindred Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.